跳至主要内容
临床试验/NCT03065309
NCT03065309已完成3 期

Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

Brasilia University Hospital1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2017年2月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
15
试验地点
1
主要终点
hemodynamic stability during rapid sequence intubation

研究概览

简要总结

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

详细描述

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life.

Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

研究设计

研究类型
Interventional
干预模型
Sequential
主要目的
Supportive Care
盲法
None

盲法说明

Participant will receive propofol before induction

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Indication of anesthesia induction

排除标准

  • Protocol violation
  • Monitoring problems

研究组 & 干预措施

Single Arm

Experimental

Patients will receive bolus dose of remifentanil before intubation

干预措施: Remifentanil (Drug)

结局指标

主要结局

hemodynamic stability during rapid sequence intubation

时间窗: from anesthesia induction up to 5 minutes

no bradycardia and no hypotension

次要结局

未报告次要终点

研究者

发起方
Brasilia University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gabriel Magalhaes Nunes Guimaraes

Head of Anesthesia department

Brasilia University Hospital

研究点 (1)

Loading locations...

相似试验